JP2017533895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533895A5 JP2017533895A5 JP2017517315A JP2017517315A JP2017533895A5 JP 2017533895 A5 JP2017533895 A5 JP 2017533895A5 JP 2017517315 A JP2017517315 A JP 2017517315A JP 2017517315 A JP2017517315 A JP 2017517315A JP 2017533895 A5 JP2017533895 A5 JP 2017533895A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- reaction
- pharmaceutically acceptable
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 238000006243 chemical reaction Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000000155 isotopic effect Effects 0.000 claims 5
- -1 4-((4- (3- (5- (tert-butyl) -2-methoxy-3- (methylsulfonamido) phenyl) ureido) naphthalen-1-yl) oxy) pyridin-2-yl Chemical group 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 208000005494 xerophthalmia Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010011017 Corneal graft rejection Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 238000006462 rearrangement reaction Methods 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 Nc1ccc2C(O)=*c2c1 Chemical compound Nc1ccc2C(O)=*c2c1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417344.7A GB201417344D0 (en) | 2014-10-01 | 2014-10-01 | New compounds |
| GB1417344.7 | 2014-10-01 | ||
| GB1510694.1 | 2015-06-18 | ||
| GBGB1510694.1A GB201510694D0 (en) | 2015-06-18 | 2015-06-18 | New compounds |
| PCT/GB2015/052877 WO2016051188A1 (en) | 2014-10-01 | 2015-10-01 | 4-(4-(4-phenylureido-naphthalen-1-yl)oxy-pyridin-2-yl)amino-benzoic acid derivative as p38 kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533895A JP2017533895A (ja) | 2017-11-16 |
| JP2017533895A5 true JP2017533895A5 (enExample) | 2018-11-08 |
| JP6662863B2 JP6662863B2 (ja) | 2020-03-11 |
Family
ID=54337298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517316A Expired - Fee Related JP6608918B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 |
| JP2017517315A Expired - Fee Related JP6662863B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としての４−（４−（４−フェニルウレイドナフタレン−１−イル）オキシピリジン−２−イル）アミノ安息香酸誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517316A Expired - Fee Related JP6608918B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US9499486B2 (enExample) |
| EP (2) | EP3201180A1 (enExample) |
| JP (2) | JP6608918B2 (enExample) |
| KR (2) | KR20170063783A (enExample) |
| CN (2) | CN106999478A (enExample) |
| AU (2) | AU2015326614B2 (enExample) |
| BR (2) | BR112017006073A2 (enExample) |
| CA (1) | CA2961870A1 (enExample) |
| EA (2) | EA032694B1 (enExample) |
| MA (2) | MA40774A (enExample) |
| MX (2) | MX373658B (enExample) |
| WO (2) | WO2016051187A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| NZ706154A (en) | 2010-02-01 | 2016-09-30 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| JP2014528404A (ja) | 2011-10-03 | 2014-10-27 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| MX363949B (es) * | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Inhibidor de quinasa. |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| EP3105222B1 (en) | 2014-02-14 | 2018-04-11 | Respivert Limited | Aromatic heterocyclic compounds as antiinflammatory compounds |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| CA3015978A1 (en) * | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3122371A1 (en) | 2018-12-07 | 2020-06-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| WO2021155100A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4175676A4 (en) * | 2020-07-06 | 2024-08-28 | Vivtex Corporation | MUCO-PENETRATING FORMULATIONS |
| JP2024506041A (ja) * | 2021-02-08 | 2024-02-08 | ボシュ ヘルス アイルランド リミテッド | 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド |
| IL306101A (en) * | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
| EP4705280A1 (en) * | 2023-05-02 | 2026-03-11 | Purdue Research Foundation | Diaryl urea-based compounds and related compositions and methods of use in the treatment of diabetes mellitus and neurodegenerative disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1028953A1 (en) | 1997-11-03 | 2000-08-23 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| ATE538794T1 (de) * | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| PL350357A1 (en) | 1999-03-12 | 2002-12-02 | Boehringer Ingelheim Pharma | Heterocyclic urea and related compounds useful as anti−inflammatory agents |
| EP1200411B1 (en) | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| JP4955171B2 (ja) * | 1999-11-16 | 2012-06-20 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての尿素誘導体 |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| MXPA03009000A (es) * | 2001-04-13 | 2004-02-12 | Boehringer Ingelheim Pharma | Compuestos benzo-fusionados 1,4-disustituidos. |
| CA2490819A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| JP2004531571A (ja) | 2001-05-25 | 2004-10-14 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物 |
| ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| JP4629978B2 (ja) | 2002-02-25 | 2011-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物 |
| AR037647A1 (es) * | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| CA2494824A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
| CA2530776A1 (en) | 2003-06-30 | 2005-01-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process of making di-aryl urea compounds |
| EP1658060A2 (en) | 2003-08-22 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating copd and pulmonary hypertension |
| EP1670787B1 (en) | 2003-09-11 | 2012-05-30 | iTherX Pharma, Inc. | Cytokine inhibitors |
| WO2005044825A1 (en) | 2003-10-21 | 2005-05-19 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
| WO2005051366A2 (en) * | 2003-11-28 | 2005-06-09 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| GB0327734D0 (en) * | 2003-11-28 | 2003-12-31 | Novartis Ag | Organic compounds |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| TW200740820A (en) | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| TWI325423B (en) | 2005-10-28 | 2010-06-01 | Lilly Co Eli | Kinase inhibitors |
| US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010067130A1 (en) | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| JP5913093B2 (ja) * | 2009-05-21 | 2016-04-27 | アストラゼネカ アクチボラグ | 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用 |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| AU2011252739B2 (en) | 2010-05-11 | 2015-05-07 | Breville Pty Limited | Improved espresso machine method and apparatus |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| JP2014528404A (ja) | 2011-10-03 | 2014-10-27 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 |
| PE20141370A1 (es) | 2011-12-09 | 2014-10-17 | Chiesi Farma Spa | Inhibidores de quinasa |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| MX363949B (es) | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Inhibidor de quinasa. |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| EP3102283B1 (en) * | 2014-02-05 | 2018-02-28 | Boston Scientific Neuromodulation Corporation | System for delivering modulated sub-threshold therapy to a patient |
| EP3105222B1 (en) | 2014-02-14 | 2018-04-11 | Respivert Limited | Aromatic heterocyclic compounds as antiinflammatory compounds |
| EP3201189A1 (en) | 2014-10-01 | 2017-08-09 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
-
2015
- 2015-09-30 MA MA040774A patent/MA40774A/fr unknown
- 2015-09-30 MA MA040775A patent/MA40775A/fr unknown
- 2015-10-01 EA EA201790660A patent/EA032694B1/ru not_active IP Right Cessation
- 2015-10-01 JP JP2017517316A patent/JP6608918B2/ja not_active Expired - Fee Related
- 2015-10-01 EA EA201790658A patent/EA035478B1/ru not_active IP Right Cessation
- 2015-10-01 MX MX2017004129A patent/MX373658B/es active IP Right Grant
- 2015-10-01 MX MX2017004128A patent/MX2017004128A/es unknown
- 2015-10-01 CA CA2961870A patent/CA2961870A1/en active Pending
- 2015-10-01 BR BR112017006073A patent/BR112017006073A2/pt not_active Application Discontinuation
- 2015-10-01 AU AU2015326614A patent/AU2015326614B2/en not_active Ceased
- 2015-10-01 JP JP2017517315A patent/JP6662863B2/ja not_active Expired - Fee Related
- 2015-10-01 AU AU2015326543A patent/AU2015326543B2/en not_active Ceased
- 2015-10-01 WO PCT/GB2015/052876 patent/WO2016051187A1/en not_active Ceased
- 2015-10-01 BR BR112017005531A patent/BR112017005531A2/pt not_active Application Discontinuation
- 2015-10-01 WO PCT/GB2015/052877 patent/WO2016051188A1/en not_active Ceased
- 2015-10-01 EP EP15782018.4A patent/EP3201180A1/en not_active Withdrawn
- 2015-10-01 US US14/872,807 patent/US9499486B2/en not_active Expired - Fee Related
- 2015-10-01 KR KR1020177010961A patent/KR20170063783A/ko not_active Withdrawn
- 2015-10-01 KR KR1020177011685A patent/KR20170057445A/ko not_active Ceased
- 2015-10-01 EP EP15782017.6A patent/EP3201179A1/en not_active Withdrawn
- 2015-10-01 US US14/872,527 patent/US9751837B2/en not_active Expired - Fee Related
- 2015-10-01 CN CN201580053439.3A patent/CN106999478A/zh active Pending
- 2015-10-01 CN CN201580053462.2A patent/CN107001274A/zh active Pending
-
2016
- 2016-10-12 US US15/291,359 patent/US9822076B2/en not_active Expired - Fee Related
-
2017
- 2017-05-24 US US15/604,258 patent/US10125100B2/en active Active
-
2018
- 2018-07-13 US US16/035,502 patent/US10392346B2/en active Active
-
2019
- 2019-07-10 US US16/508,253 patent/US10941115B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533895A5 (enExample) | ||
| JP2016519680A5 (enExample) | ||
| EP3752495B1 (en) | Pyridine derivatives and their use for treating hiv infection | |
| JP6608918B2 (ja) | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 | |
| JP2017535525A5 (enExample) | ||
| TWI259079B (en) | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives | |
| JP2013545817A5 (enExample) | ||
| CN109890808A (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| JP2019517463A5 (enExample) | ||
| JP2013540776A5 (enExample) | ||
| JP2013545816A5 (enExample) | ||
| JP2017502033A5 (enExample) | ||
| JP2017536395A5 (enExample) | ||
| JP2012530713A5 (enExample) | ||
| TW201034669A (en) | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors | |
| JP2017141281A5 (ja) | オキシトシン／バソプレッシンＶ１ａレセプターのアンタゴニストとしてのピロリジン誘導体を含有する医薬組成物 | |
| JP2017532965A5 (enExample) | ||
| TW200304824A (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| JP2019505529A5 (enExample) | ||
| JP2020516697A (ja) | 核受容体の効能剤であるイソオキサゾール誘導体及びその用途 | |
| TWI694986B (zh) | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 | |
| JP2019514861A5 (enExample) | ||
| CN103097365B (zh) | 作为鞘氨醇-1-磷酸(s1p)受体上的配体的5-(联苯-4-基)-3-苯基-1,2,4-噁二唑基衍生物 | |
| IL296182A (en) | Inhibitors of human immunodeficiency virus replication | |
| EP3049406A1 (de) | Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen |